Valerio Therapeutics

ALVIO

Company Profile

  • Business description

    Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.

  • Contact

    49, Boulevard du General
    Martial Valin
    Paris75015
    FRA

    T: +33 145587600

    https://www.valeriotx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    38

Stocks News & Analysis

stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks

Cheap ASX energy play boasts strong cash flows and balance sheet

Markets appear overly bearish on the company despite the company having attracting growth options.
stocks

Market overreacts to earnings miss from moated ASX retailer

Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,207.3032.70-0.35%
CAC 407,727.42115.62-1.47%
DAX 4024,196.5176.61-0.32%
Dow JONES (US)45,282.47349.27-0.77%
FTSE 1009,274.1547.25-0.51%
HKSE25,524.92304.99-1.18%
NASDAQ21,449.2947.24-0.22%
Nikkei 22542,394.40413.42-0.97%
NZX 50 Index12,957.98121.52-0.93%
S&P 5006,439.3227.59-0.43%
S&P/ASX 2008,935.6031.30-0.35%
SSE Composite Index3,868.3815.18-0.39%

Market Movers